Maintenance treatment with interferon in multiple myeloma
Sübutlu məlumatların xülasələri
28.09.2012 • Sonuncu dəyişiklik 28.09.2012
Editors
There appears to be no significant survival advantage of interferon in the maintenance treatment of multiple myeloma.
A systematic review including 6 RCTS with a total of 812 subjects was abstracted in DARE. The pooled weighted mean lifetime survival for the control group was 3.42 years per patient, and for the interferon-treated group it was 3.42 (or 3.87, 95% CI 2.88 to 4.06 estimated by the method of Simes).
Comment: The quality of evidence is downgraded by limitations in review methodology.
Ədəbiyyat
- Trippoli S, Becagli P, Messori A, Trendi E. Maintenance treatment with interferon in multiple myeloma: a survival meta-analysis. Clin Drug Invest 1997;14:392-399.